Key result
Growth hormone administration in children with idiopathic short stature shows a dose-dependent first-year growth response, though effects on final height remain uncertain in uncontrolled studies.
Why the study?
Does growth hormone administration improve growth response and final height in children with idiopathic short stature?
Does growth hormone administration improve growth response and final height in children with idiopathic short stature?
Growth hormone therapy in children with idiopathic short stature shows a dose-dependent effect on first-year growth and likely final height.
May support short-term GH dosing in idiopathic short stature; leaves open final height gains from uncontrolled data.
This article reviews the available data on the effect of growth hormone (GH) administration on the growth of children with idiopathic short stature. The 1st year growth response appears clearly dose dependent, if the mean values from various clinical trials are combined. Dose dependency has also been shown in prospective trials. The dose dependency of the long-term growth response was less convincing in a large prospective study. The effect on final height cannot be proven with certainty in uncontrolled studies. If all available results from clinical trials are combined, a positive correlation between response and dose appears likely.
No takes yet. Share an insight, caveat, or question.
Kamp et al. (1998) conducted a review in Idiopathic short stature. Growth hormone (GH) was evaluated on Growth response and final height. Growth hormone administration in children with idiopathic short stature shows a dose-dependent first-year growth response, though effects on final height remain uncertain in uncontrolled studies.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: